Indian American Anjali Pandey, head of medicinal chemistry at Sudo Biosciences, and an accomplished biopharmaceutical R&D leader, scientist, and inventor, says artificial intelligence (AI) will not only change the time course taken by biotech or pharma industries to drug discovery, but will also bring the cost down.
Artificial Intelligence (AI) will have a significant impact on the biopharma industry in the next couple of years. There was a lag, so big biopharma firms have a lot to catch up in putting AI to optimal use, believes Indian American Sachin Sontakke, Senior Director of Information Technology, Cloud, Data and Analytics at Gilead Sciences.
